Home › Therapeutic areas › GI/Hepatology

GI/Hepatology (17 companies · 11 conditions)

Conditions

Companies

Ticker Company Therapeutic areas In GI/Hepatology Lead stage Mkt cap Programs
ABSI Absci DermatologyGI/Hepatology+1 1 Phase 1 $1.31B 6
ACRS Aclaris Therapeutics DermatologyGI/Hepatology+1 Rare 1 Phase 2 $536M 7
ACRV Acrivon Therapeutics GI/HepatologyOncology Rare 1 Phase 2 $61.4M 9
ALT Altimmune GI/HepatologyMetabolic+1 1 Phase 3 $298M 3
ANAB AnaptysBio DermatologyGI/Hepatology+2 Rare 2 Approved $1.36B 9
APGE Apogee Therapeutics DermatologyGI/Hepatology+1 Rare 1 Phase 2 — 9
ARDX Ardelyx GI/HepatologyRenal 2 Approved $799M 4
CMMB Chemomab Therapeutics GI/HepatologyImmunology+1 Rare 1 Phase 2 $13.2M 4
IRON Disc Medicine GI/HepatologyHematology+2 Rare 1 Phase 3 $3.49B 9
ENTX Entera Bio GI/HepatologyMetabolic Rare 1 Phase 2 $522M 4
ETON Eton Pharmaceuticals GI/HepatologyInfectious Disease+3 Rare 2 Approved $1.84B 17
FBRX Forte Biosciences DermatologyGI/Hepatology 1 Phase 2 — 3
IMUX Immunic GI/HepatologyNeurology 1 Phase 3 $116M 4
MESO Mesoblast CardiovascularGI/Hepatology+2 Rare 1 Approved $1.54B 5
PRME Prime Medicine GI/HepatologyRespiratory Rare 1 Phase 1 $699M 3
PCSA Processa Pharmaceuticals GI/HepatologyImmunology+2 Rare 1 Phase 2 $4.8M 7
VNDA Vanda Pharmaceuticals CardiovascularDermatology+6 Rare 2 Approved $230M 27